Trade War

Australia keeps device supply tied to evidence of European certificate extensions

November market notices distinguish low-risk device changes and withdrawals from safety recalls, while sponsors must substantiate the European certificates supporting Australian supply.

Companies and supply chains 18 November 2026

Australia's medical-device regulator is using its market-notification service to show how Europe's certification transition affects local supply. The service, updated on 2 November 2026, covers low-risk changes and notices that a device will stop being supplied in Australia because it is not moving to the European Union's newer regulatory framework. It is not a list solely of defective products.1

The Therapeutic Goods Administration says safety problems still require direct communication through the usual recall or post-market channels. The streamlined publication route is available only where the relevant conditions are met, including that the changes arise from regulatory requirements rather than unsafe or defective devices.1

Printed expiry dates do not settle eligibility

The TGA's August guidance treats qualifying European certificates as valid for existing Australian Register of Therapeutic Goods entries despite their printed expiry dates. Sponsors must substantiate eligibility for the European extension when requested.2

Sponsors must notify the TGA within 60 days of learning that a supporting European certificate is no longer valid, including through suspension, cancellation or withdrawal. An Australian register entry without valid conformity assessment certification may face suspension or cancellation.2

The practical trade connection is documentary: an overseas manufacturer's certification status can determine whether its Australian sponsor can maintain the existing supply route. The European certificate is evidence supporting Australian regulation, rather than a substitute for the Australian register entry.2

European oversight continues during the transition

The European Commission's French procurement factsheet explains that qualifying legacy devices remain under the supervision of the body responsible for their conformity assessment during the transition. Its description is explicit:

restent soumis à la surveillance de l’organisme notifié

Remain subject to supervision by the notified body.3

The European timetable generally runs to the end of 2027 for higher-risk devices and the end of 2028 for other specified categories, subject to eligibility conditions and exceptions. Manufacturers had to lodge the relevant application and sign an agreement with a notified body by the earlier prescribed deadlines. The extension therefore is conditional, rather than permission for any old certificate to support new sales indefinitely.3

Supply planning extends beyond Europe

In its supply-disruption guidance, published in July 2024 and still available, the TGA identifies certification costs and delays as reasons some manufacturers may withdraw devices or decline to renew every product. That guidance describes a risk and response framework; it does not quantify current Australian shortages.4

The agency also accepts approvals from several comparable regulators, including those in the United States, Canada, Singapore and Japan. It encourages health services to work with sponsors and health departments on alternatives. The open question for a device approaching its transition deadline is whether its supplier will secure the required certification, use another accepted regulatory route or notify customers that supply will end.4

Sources

  1. Therapeutic Goods Administration. EU MDR transition web publication service. 2 November 2026Australia's camp · government guidance
  2. Therapeutic Goods Administration. EU MDR transition extension. 25 August 2026Australia's camp · government guidance
  3. European Commission. Fiche d’information relatifs à l’écosystème des marchés publics relatifs aux dispositifs médicaux et aux dispositifs médicaux de diagnostic in vitro [Factsheet for the medical-device procurement ecosystem]. Accessed 18 November 2026European Union's camp · government guidance · in French
  4. Therapeutic Goods Administration. How we are managing medical device supply disruptions resulting from changes in Europe. 17 July 2024Australia's camp · government guidance

All articles